Key events, in time order
Chatter of LLY tie-up and Centerview re-engagement follow post-financing independence push
Twitter retweet confirms meaningful clinical benefit in ABTECT maintenance Part 2, extending prior efficacy narrative
Jefferies raises PT to $108, views non-NMSC cases as bad luck; market awaits Part 2 data
Independent source adds pre-event positioning detail, attributing selling pressure to mutual funds rather than pods
None yet
None yet
The author is a net seller of $ABVX, citing the prolonged lack of M&A activity as a reason for their decision. This reflects a shift from previous holding patterns.
Main discussion
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
French biotech developing small-molecule drugs for inflammatory, infectious, and cancer diseases; lead candidate ABX464 in Phase IIb trials for ulcerative colitis and Crohn's disease.
No revenue. Burning EUR 0.25B operating losses annually (2025), with losses accelerating. Pure R&D spend; no commercial products generating cash.
None yet—pre-revenue biotech with no approved drugs, no market position, and no defensible advantage until clinical success. Competitors like Roche, Gilead, and Regeneron have established IBD and viral portfolios.
Sell (sector percentile 13) — value D, growth C-, profitability D-, momentum C+, revisions A. Updated daily, sector-relative, identical for every user.
